Surgery Partners Holds Annual Meeting, Re-elects Directors

Surgery Partners ( (SGRY) ) just unveiled an update.

On June 6, 2025, Surgery Partners held its Annual Meeting, where stockholders voted on several key proposals. The election of Class I directors resulted in the re-election of current directors John A. Deane, Teresa DeLuca, M.D., and Wayne S. DeVeydt, who will serve until the 2028 annual meeting. Additionally, stockholders approved the executive compensation on an advisory basis, the 2025 Omnibus Incentive Plan, and ratified Ernst & Young LLP as the independent registered public accounting firm for the fiscal year 2025.

The most recent analyst rating on (SGRY) stock is a Buy with a $28.00 price target. To see the full list of analyst forecasts on Surgery Partners stock, see the SGRY Stock Forecast page.

Spark’s Take on SGRY Stock

According to Spark, TipRanks’ AI Analyst, SGRY is a Neutral.

Surgery Partners receives a solid score driven by strong cash flow performance and positive sentiment from its latest earnings call, which highlighted growth in revenue and case volumes. However, high leverage and a negative P/E ratio temper the overall outlook. The technical analysis suggests a neutral market sentiment.

To see Spark’s full report on SGRY stock, click here.

More about Surgery Partners

Average Trading Volume: 1,028,164

Technical Sentiment Signal: Sell

Current Market Cap: $2.96B

For detailed information about SGRY stock, go to TipRanks’ Stock Analysis page.